30 closest matches · ranked by relevance
Acute Febrile Illness
Primary: The Etiologies (Bacteria, Viruses, Parasites, Fungi and Others) of Fever Illness Expressed in Percentages of Enrolled Subjects. — 621; 362; 15; 5 Participants
Febrile Illness
Primary: Proportion of Survival With Symptom Resolution — 96.9 percentage of participants
Influenza
Primary: Cost for the Medical Management of Patients — 581; 661 USD
Fever
Primary: Fever >= 100.4 — 7.5; 37.6; 9.5 percentage of participants
Fever · Infection · Inflammation
Primary: Number of Participants With Clinically-assigned Retrospective Phenotype — 655; 0 Participants
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
Fever
Primary: Number of Participants With Admission to Hospital Due to Parental High Levels of Worry — 87 Participants
Malaria · Seizures · Coma
Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001
Fever · Brain Hemorrhage
Primary: Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care — 100.8; 100.3; 99.9; 99.5 degrees F
Subarachnoid Hemorrhage · Subdural Hematoma · Traumatic Brain Injury
Primary: Temperature Burden — 37.8; 37.7 Temperature in degrees Celsius
Fever · Critical Illness
Primary: Core Body Temperature — 38.4; 37.9 degrees Celsius — p=0.002
Fever
Primary: Child Temperature (Degrees C)Over 6 Hours — 38.5; 37.2; 36.9 degrees Celcius — p=<0.001
Influenza · Otitis Media · Lower Resp Tract Infection
Primary: Hospitalization — 26; 2 Participants
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Relapsing Multiple Sclerosis
Primary: Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu-like Symptom Score — 8.5; 9.1 MSTCQ score (units on a scale)
Hematologic Neoplasms · Neutropenia · Fever
Primary: Percentage of Participants Achieving Plasma Level of Itraconazole at 1000 Nanogram Per Milliliter (ng/mL) or Higher After Administration of Study Treatment — 68.0…
Relapsing Multiple Sclerosis
Primary: Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall Population — 10.3 percentage of participants — p=<0.0001
Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 136.2; 114.1; 117.4 Hours — p=0.377
Enteric Fever
Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants
Fever
Primary: Accuracy of Temperature Measurements Using Masimo INVSENSOR00063 — -0.24; 0.85; 0.05 Degrees Celsius
Encephalitis · Meningitis
Primary: Total Number of Cases With at Least One Provider Response — 98; 58 cases
Fever
Primary: The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2) — 0.3; 0.6 Degrees Celsius
Fever
Primary: Accuracy of Masimo RAD-GT Temperature Measurments — -0.24; 0.85; 0.09 Degrees Celsius
Children Who Present to the ED With Minor Febrile Illnesses
Primary: Recidivism — 6; 3 number of return visits within 72 ho
Upper Respiratory Infections
Primary: Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup — 34.6 mm
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants
Infectious Gastroenteritis
Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants
Fever Without Source
Primary: Antibiotic Prescription Rate — 54; 59 participants — p=1
Influenza
Primary: Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever — 120; 11 Participants
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants